The new year doesn’t seem so new anymore. January is already almost halfway over. Before you know it, we’ll be looking ahead to 2027.
No one can slow down time. It is important to seize great opportunities as early as possible. That’s why I think the following three top growth stocks are great picks to consider buying in the first half of 2026.
Image source: Getty Images.
I really like the growth prospects Metaplatforms(NASDAQ:META) has with its Meta Ray-Ban Display glasses. These are the first artificial intelligence (AI) glasses with a private display integrated into the lens and a neural band wrist control. I consider Meta’s first mover advantage a big plus.
Is Meta CEO Mark Zuckerberg correct that glasses are “the ideal form factor for AI”? Yeah. No other device can process everything a user sees and hears. I’m not at all surprised that Meta sold so many of its glasses in the US that it had to delay the global rollout.
While I’m excited about Meta’s latest AI glasses, they’re not the main reason to buy this stock at the moment. That honor belongs to the company’s huge user base, which gives it pricing power with advertisers. On average, 3.54 billion people used Meta apps every day in September 2025. This number reflects an 8% year-over-year increase. This also represents almost 43% of the world’s population.
These users don’t seem to disappear. As long as that remains the case, Meta will generate billions of dollars in revenue and profits – and the company’s stock should perform well. AI glasses and Meta’s big bet on AI superintelligence (AI) are just the icing on the cake.
If you’re looking for a bargain in AI stocks, you might want to buy shares of Micron technology(name: mu). It is forward price/earnings ratio is 10.8. Micron’s price-to-earnings-to-growth (PEG) ratio, based on analysts’ five-year earnings growth projections, is remarkably low at 0.6.
Why is Micron stock so cheap? Its price is based on an outdated paradigm that views memory as a simple cyclical product. This perspective was correct until high-bandwidth memory (HBM) became such a critical component of AI chips and the demand for AI chips exploded.
Micron revealed during its first quarter fiscal 2026 earnings call that its entire planned HBM supply for the year is already fully allocated. The future also looks promising. Management estimates that the total addressable market for HBM will increase by a compound annual growth rate of approximately 40% through 2028.
The good news isn’t limited to HBM either. Micron expects approximately 20% growth in DRAM (dynamic random access memory) and NAND (non-and) memory shipments in 2026. CEO Sanjay Mehrotra believes that “overall industry supply will remain significantly below demand for the foreseeable future.”
Amazing pharmaceutical products(NASDAQ:MIRM) is the odd one out on the list. The drugmaker’s market capitalization of $4.5 billion is only a fraction of that of Meta and Micron. However, I predict that 2026 will be a big year for Mirum.
The company is coming off a tremendous performance in 2025. Mirum shares have soared 91% in the last year. The year 2026 has also started well so far. Investors should closely watch three key developments this year.
First, market momentum for Mirum’s rare liver disease drug Livmarli is expected to continue. Sales increased 56% year-over-year to $92.2 million in Q3 2025. I believe Livmarli is poised to become Mirum’s first blockbuster drug.
Second, Mirum plans to release results from its clinical study evaluating voloxibat in primary sclerosing cholangitis in the second quarter of 2026. If all goes well, the company could file for regulatory approval in the United States in the second half of the year.
Third, Mirum’s pending acquisition of Bluejay Therapeutics could begin to bear fruit quickly. This deal is expected to close in the first quarter of 2026. Bluejay plans to report phase 3 results of brelovitug treatment for chronic hepatitis delta virus (HDV) later in the year. I think these results could be an important catalyst for Mirum stock.
Before buying Mirum Pharmaceuticals stock, consider this:
THE Motley Fool Stock Advisor The analyst team has just identified what they think is the 10 best stocks for investors to buy now…and Mirum Pharmaceuticals was not one of them. The 10 selected stocks could produce monster returns in the years to come.
Consider when Netflix made this list on December 17, 2004…if you had invested $1,000 at the time of our recommendation, you would have $482,451!* Or when Nvidia made this list on April 15, 2005…if you had invested $1,000 at the time of our recommendation, you would have $1,133,229!*
Now it’s worth noting Equity Advisor the total average return is 968% — an overwhelming market outperformance compared to the 197% for the S&P 500. Don’t miss the latest top 10, available with Equity Advisorand join an investor community built by individual investors for individual investors.
Keith Speights has positions in meta-platforms. The Motley Fool holds positions and recommends Meta Platforms and Mirum Pharmaceuticals. The Mad Motley has a disclosure policy.
